{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:24:13Z","timestamp":1790447053243,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science, and Technology, Japan","award":["23K07237"],"award-info":[{"award-number":["23K07237"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Since 2016, splice-switching therapy, in which splicing is controlled by antisense oligonucleotides, has been applied in clinical practice for spinal muscular atrophy and Duchenne muscular dystrophy. In the former disease, this therapy induces exon inclusion, while, in the latter, it induces exon skipping, leading expression of functional proteins. Basic and clinical studies of splice-switching therapy for many monogenic diseases have now been conducted. The molecular mechanisms of splice-switching therapy include not only the induction of exon inclusion and skipping, but also the induction of pseudoexon skipping and suppression of splicing sites generated by mutations. In addition, therapies that alter protein function by regulating splicing are being investigated not only for monogenic diseases but also for non-monogenic ones such as cancer and immune-related disorders. It is expected that many of these basic studies will be translated into clinical applications. This review describes the current status of basic research and clinical applications of splice-switching therapy to promote the development of treatments for noncurable diseases.<\/jats:p>","DOI":"10.3390\/ijms26052270","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T03:26:21Z","timestamp":1741058781000},"page":"2270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Expansion of Splice-Switching Therapy with Antisense Oligonucleotides"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-7185","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeshima","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147672","DOI":"10.1016\/j.gene.2023.147672","article-title":"Birth and death view of DNA, RNA, and proteins","volume":"883","author":"Kumari","year":"2023","journal-title":"Gene"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI117693","article-title":"Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe","volume":"95","author":"Takeshima","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","article-title":"Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"JMA J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","article-title":"Spliced segments at the 5\u2032 terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5\u2032 ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1261\/rna.876308","article-title":"Splicing regulation: From a parts list of regulatory elements to an integrated splicing code","volume":"14","author":"Wang","year":"2008","journal-title":"RNA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1101\/gad.7.3.407","article-title":"The role of exon sequences in splice site selection","volume":"7","author":"Watakabe","year":"1993","journal-title":"Genes. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and Regulation of Alternative Pre-mRNA Splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/bfgp\/elr020","article-title":"RNA splicing: Disease and therapy","volume":"10","author":"Douglas","year":"2011","journal-title":"Brief. Funct. Genom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0387-7604(01)00326-6","article-title":"Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient","volume":"23","author":"Takeshima","year":"2001","journal-title":"Brain Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1203\/01.pdr.0000215047.51278.7c","article-title":"Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy","volume":"59","author":"Takeshima","year":"2006","journal-title":"Pediatr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Maeta, K., Farea, M., Nishio, H., and Matsuo, M. (2022). An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of the MSTN Gene Inhibits Pre-mRNA Maturation to Act as a Novel Myostatin Inhibitor. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095016"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: A phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JND-150109","article-title":"Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients\u2019 Cells","volume":"2","author":"Barthelemy","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acn3.738","article-title":"Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation","volume":"6","author":"Dominov","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e99357","DOI":"10.1172\/jci.insight.99357","article-title":"Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers","volume":"3","author":"Wyatt","year":"2018","journal-title":"JCI Insight"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2015.8","article-title":"Ameliorating pathogenesis by removing an exon containing a missense mutation: A potential exon-skipping therapy for laminopathies","volume":"22","author":"Scharner","year":"2015","journal-title":"Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtn.2020.05.029","article-title":"Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD","volume":"21","author":"Aguti","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/hmg\/ddac286","article-title":"Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant","volume":"32","author":"Enkhjargal","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41467-023-37619-1","article-title":"Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","article-title":"AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1","volume":"48","author":"Konieczny","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e154108","DOI":"10.1172\/jci.insight.154108","article-title":"A pathogenic proteolysis-resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function","volume":"7","author":"Kim","year":"2022","journal-title":"JCI Insight"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/brain\/awad349","article-title":"Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model","volume":"147","author":"Yuan","year":"2024","journal-title":"Brain"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, D., Aung-Htut, M.T., Ham, K.A., Fletcher, S., and Wilton, S.D. (2020). A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson\u2019s Disease Arising from Parkin Mutations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197282"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.omtn.2020.06.027","article-title":"Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice","volume":"21","author":"Korecka","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Molinari, E., Ramsbottom, S.A., Srivastava, S., Booth, P., Alkanderi, S., McLafferty, S.M., Devlin, L.A., White, K., Gunay-Aygun, M., and Miles, C.G. (2019). Targeted exon skipping rescues ciliary protein composition defects in Joubert syndrome patient fibroblasts. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-47243-z"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2302534120","DOI":"10.1073\/pnas.2302534120","article-title":"Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP","volume":"120","author":"Shah","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/hmg\/ddz285","article-title":"Naturally occurring NOTCH3 exon skipping attenuates NOTCH3 protein aggregation and disease severity in CADASIL patients","volume":"29","author":"Gravesteijn","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/brain\/aww011","article-title":"Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: In vitro proof of concept","volume":"139","author":"Rutten","year":"2016","journal-title":"Brain"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"McIntosh, C.S., Aung-Htut, M.T., Fletcher, S., and Wilton, S.D. (2019). Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215434"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yamada, M., Maeta, K., Suzuki, H., Kurosawa, R., Takenouchi, T., Awaya, T., Ajiro, M., Takeuchi, A., Nishio, H., and Hagiwara, M. (2024). Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-56704-z"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.omtn.2022.10.026","article-title":"Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro","volume":"30","author":"Catasus","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-024-07310-6","article-title":"Antisense oligonucleotide therapeutic approach for Timothy syndrome","volume":"628","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e163464","DOI":"10.1172\/JCI163464","article-title":"A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T","volume":"133","author":"Ito","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","article-title":"Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease","volume":"7","author":"Bergsma","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/nat.2024.0014","article-title":"Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria","volume":"34","author":"Alvarez","year":"2024","journal-title":"Nucleic Acid. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102101","DOI":"10.1016\/j.omtn.2023.102101","article-title":"Regulating PCCA gene expression by modulation of pseudoexon splicing patterns to rescue enzyme activity in propionic acidemia","volume":"35","author":"Dembic","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/humu.21118","article-title":"Pseudoexon exclusion by antisense therapy in methylmalonic aciduria (MMAuria)","volume":"30","author":"Perez","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1089\/hum.2020.034","article-title":"Development of an Antisense Oligonucleotide-Mediated Exon Skipping Therapeutic Strategy for Mucolipidosis II: Validation at RNA Level","volume":"31","author":"Matos","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ymgme.2016.08.007","article-title":"The prevalent deep intronic c. 639+919 G>A GLA mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2\/B1 to a splicing silencer","volume":"119","author":"Palhais","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E993","DOI":"10.1002\/humu.21119","article-title":"Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease","volume":"30","author":"Coll","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2012.264","article-title":"Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo","volume":"21","author":"Disterer","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, H., Wang, C., Che, R., Zheng, B., Zhou, W., Huang, S., Jia, Z., Zhang, A., Zhao, F., and Ding, G. (2023). A Potential Therapy Using Antisense Oligonucleotides to Treat Autosomal Recessive Polycystic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041428"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41591-021-01297-7","article-title":"Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: A case report","volume":"27","author":"Cideciyan","year":"2021","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.omtn.2023.02.020","article-title":"Antisense oligonucleotide therapy corrects splicing in the common Stargardt disease type 1-causing variant ABCA4 c.5461-10T>C","volume":"31","author":"Kaltak","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41436-018-0414-9","article-title":"Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides","volume":"21","author":"Sangermano","year":"2019","journal-title":"Genet. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Grainok, J., Pitout, I.L., Chen, F.K., McLenachan, S., Heath Jeffery, R.C., Mitrpant, C., and Fletcher, S. (2024). A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063391"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.omtn.2020.07.036","article-title":"Antisense Oligonucleotide- and CRISPR-Cas9-Mediated Rescue of mRNA Splicing for a Deep Intronic CLRN1 Mutation","volume":"21","author":"Panagiotopoulos","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e2217423120","DOI":"10.1073\/pnas.2217423120","article-title":"Deep intronic founder mutations identified in the ERCC4\/XPF gene are potential therapeutic targets for a high-frequency form of xeroderma pigmentosum","volume":"120","author":"Senju","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2401781121","DOI":"10.1073\/pnas.2401781121","article-title":"Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa","volume":"121","author":"Pironon","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hainzl, S., Trattner, L., Liemberger, B., Bischof, J., Kocher, T., Ablinger, M., Nystrom, A., Obermayer, A., Klausegger, A., and Guttmann-Gruber, C. (2024). Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020761"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study","volume":"141","author":"Bornert","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.dld.2022.04.002","article-title":"Antisense oligonucleotides rescue an intronic splicing variant in the ABCB11 gene that causes progressive familial intrahepatic cholestasis type 2","volume":"54","author":"Zheng","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Abdelrahman, A., Nielsen, M.W., Stage, M.H., and Arnspang, E.C. (2023). Nuclear envelope morphology change upon repetitive treatment with modified antisense oligonucleotides targeting Hutchinson-Gilford Progeria Syndrome. Biochem. Biophys. Rep., 33.","DOI":"10.1016\/j.bbrep.2022.101411"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2114858118","DOI":"10.1073\/pnas.2114858118","article-title":"Exon-skipping antisense oligonucleotides for cystic fibrosis therapy","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1093\/nar\/gkaa229","article-title":"Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria","volume":"48","author":"Halloy","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_66","first-page":"60","article-title":"Fukutin and alpha-dystroglycanopathies","volume":"24","author":"Toda","year":"2005","journal-title":"Acta Myol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature10456","article-title":"Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy","volume":"478","author":"Kobayashi","year":"2011","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nsmb.1720","article-title":"Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy","volume":"17","author":"Du","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: A practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2024.5678","article-title":"Aberrant alternative splicing in cancer: Splicing events and their regulatory mechanisms (Review)","volume":"65","author":"Sun","year":"2024","journal-title":"Int. J. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"147330","DOI":"10.1016\/j.gene.2023.147330","article-title":"Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells","volume":"866","author":"Wang","year":"2023","journal-title":"Gene"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Balachandran, A.A., Raguraman, P., Rahimizadeh, K., and Veedu, R.N. (2023). Splice-Switching Antisense Oligonucleotides Targeting Extra- and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123299"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-021-00245-5","article-title":"Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma","volume":"6","author":"Khurshid","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cell.2017.03.007","article-title":"Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk","volume":"169","author":"Briggs","year":"2017","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1261\/rna.079137.122","article-title":"Antisense modulation of IL7R splicing to control sIL7R expression in human CD4(+) T cells","volume":"28","author":"Schott","year":"2022","journal-title":"RNA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.1608520113","article-title":"Exon skipping of FcepsilonRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy","volume":"113","author":"Cruse","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e17157","DOI":"10.15252\/emmm.202217157","article-title":"ASO targeting RBM3 temperature-controlled poison exon splicing prevents neurodegeneration in vivo","volume":"15","author":"Preussner","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"H860","DOI":"10.1152\/ajpheart.00745.2023","article-title":"An antisense oligonucleotide efficiently suppresses splicing of an alternative exon in vascular smooth muscle in vivo","volume":"326","author":"Meddeb","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2016.06.010","article-title":"Overexpression of the short endoglin isoform reduces renal fibrosis and inflammation after unilateral ureteral obstruction","volume":"1862","author":"Oujo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gerrits, T., Dijkstra, K.L., Bruijn, J.A., Scharpfenecker, M., Bijkerk, R., and Baelde, H.J. (2024). Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis. Biochim. Biophys. Acta Mol. Basis Dis., 1870.","DOI":"10.1016\/j.bbadis.2024.167186"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cmet.2024.04.003","article-title":"TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis","volume":"36","author":"Isaac","year":"2024","journal-title":"Cell Metab."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Trundle, J., Lu-Nguyen, N., Malerba, A., and Popplewell, L. (2024). Targeted Antisense Oligonucleotide-Mediated Skipping of Murine Postn Exon 17 Partially Addresses Fibrosis in D2.mdx Mice. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116113"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41416-020-0951-2","article-title":"Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer","volume":"123","author":"Li","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/ijc.30574","article-title":"Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action","volume":"140","author":"Smith","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"111280","DOI":"10.1016\/j.intimp.2023.111280","article-title":"An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3","volume":"126","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Fukushima, S., Farea, M., Maeta, K., Rani, A.Q.M., Fujioka, K., Nishio, H., and Matsuo, M. (2020). Dual Fluorescence Splicing Reporter Minigene Identifies an Antisense Oligonucleotide to Skip Exon v8 of the CD44 Gene. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239136"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Aung-Htut, M.T., Comerford, I., Johnsen, R., Foyle, K., Fletcher, S., and Wilton, S.D. (2019). Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49385-6"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Eilers, W., Cleasby, M., and Foster, K. (2021). Development of antisense-mediated myostatin knockdown for the treatment of insulin resistance. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-81222-7"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/mtna.2014.7","article-title":"Targeting TGF-beta Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-beta Type I Receptor","volume":"3","author":"Kemaladewi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1038\/mtna.2013.69","article-title":"Novel Ex Vivo Culture Method for the Study of Dupuytren\u2019s Disease: Effects of TGFbeta Type 1 Receptor Modulation by Antisense Oligonucleotides","volume":"3","author":"Karkampouna","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2059513120908857","DOI":"10.1177\/2059513120908857","article-title":"Exon skipping of TGFbetaRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts","volume":"6","author":"Raktoe","year":"2020","journal-title":"Scars Burn. Heal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:40Z","timestamp":1760028400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":93,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26052270"],"URL":"https:\/\/doi.org\/10.3390\/ijms26052270","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}